PDHB

Across TCGA pan-cancer cohorts, PDHB mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PDHB data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDHB mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PDHB expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where PDHB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.513	0.298	.022	14	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.914	.046	6	view →
CCRCC	DFS	Median	II,III,IV	0.493	0.722	.028	3	view →
UCEC	DFS	Median	All	0.936	1.000	.021	2	view →
LUAD	OS	Quartile	All	1.000	0.686	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PDHB–PDAC (OS)

Open the PDAC breakdown →